DDInter973 DDInter1676
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Irinotecan {u} (Compound) treats {v} (Disease) hematologic cancer
Irinotecan {u} (Compound) binds {v} (Gene) ABCC1
Irinotecan {u} (Compound) upregulates {v} (Gene) PHLDA3
Irinotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Irinotecan {u} (Compound) downregulates {v} (Gene) PCMT1
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Irinotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Verapamil
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Irinotecan (Compound) treats hematologic cancer (Disease)
Irinotecan (Compound) binds ABCC1 (Gene)
Irinotecan (Compound) upregulates PHLDA3 (Gene)
Irinotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Irinotecan (Compound) downregulates PCMT1 (Gene)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect)
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Irinotecan may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Verapamil